ClinicalTrials.gg
RecruitingNCT07310147Updated Jan 8, 2026

Empower Your Mind to Embrace Your Life: an Online ACT Intervention for Young-Onset Parkinson's Disease

An interventional study of Empower your mind to embrace your life in Parkinson's Disease (PD), sponsored by University of Coimbra. Recruiting at 1 site in Portugal. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by University of Coimbra · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Apr 2025, registered Dec 2025).
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Parkinson Disease with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Parkinson Disease · Portugal.

Planned enrollment
41st of 51
20 · median 106
Started
2025
with 1 other
No phase
9 of 55
2 open now
Registered
54th of 55
by date

Among the 55 studies in Parkinson Disease with a site in Portugal, this one is the 41st largest by planned enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 54th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 55 studies in Parkinson Disease with a site in Portugal are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Parkinson Disease with a site in Portugal, or all of them as a file.
02

Study summary

Parkinson's disease (PD) has a substantial impact on daily life and significantly affects functioning, mental health and quality of life. Although considered a disease of the elderly, an early diagnosis is also common. Non-pharmacological interventions have been increasingly recommended for PD, including psychotherapy, with emerging evidence suggesting that Acceptance and Commitment Therapy (ACT) may be suitable to support individuals living with PD. This project aims to expand the current evidence for ACT interventions in this population by developing, implementing, and investigating the preliminary efficacy of a novel online-delivered ACT intervention (Empower your mind to embrace your life) for individuals with a diagnosis of young-onset PD. For this purpose, a feasibility study will be conducted to assess the acceptability and preliminary efficacy of the intervention across two groups (control and ACT intervention). This group-based intervention consists of eight weekly sessions and will be delivered in an online format (via videoconferencing). Outcome measurement will be assessed at pre-intervention, post-intervention, and at 3-month follow-up. When comparing changes in outcome variables between the control and intervention groups at post-treatment, improvements are expected only in the intervention group. These improvements are also expected to be maintained over time (at 3-month follow-up). Lastly, changes in psychological (in)flexibility processes are expected to predict changes in outcome variables in the intervention group. This study will provide important insights to research and clinical practice by providing data on the feasibility and preliminary efficacy of this novel ACT-based intervention for the context of young-onset PD.

Read the detailed description

Parkinson's disease (PD) is a complex, progressive neurodegenerative disease that predominantly affects movement. Although considered a disease of the elderly, an early diagnosis is also common and entails unique challenges that significantly affect several domains of life. PD is characterized by a multitude of motor (e.g., bradykinesia, resting tremor, rigidity) and non-motor symptoms (NMS, e.g., depression, pain, fatigue). Specifically, NMS have received increasing attention due to their detrimental impact on individuals' functioning, mental health outcomes and overall quality of life. In fact, NMS can be as disabling as motor PD manifestations, particularly in people with young-onset PD.

In recent years, non-pharmacological interventions have been developed with the aim of improving overall quality of life and managing NMS, including psychotherapy. In particular, third-wave psychological interventions have been applied in the context of PD with promising results, and literature has specifically highlighted Acceptance and Commitment Therapy (ACT) as a transdiagnostic model that appears to be well-suited for helping individuals with PD manage the challenges associated with their symptoms. The overarching goal of ACT is to increase psychological flexibility, a core process defined as the ability to be fully in contact with the present moment, with an accepting and nonjudgmental attitude, while behaving according to one's values. Evidence supports ACT's efficacy in several chronic physical illnesses, but few studies have implemented such interventions in adults diagnosed with PD. Despite promising results, current evidence remains limited and preliminary.

Additionally, literature highlighted the relevance of technology-supported psychological interventions in providing more cost-effective interventions for healthcare systems, especially in the context of chronic conditions. Notably, videoconferencing has been shown to be effective in overcoming face-to-face intervention-related barriers (e.g., mobility limitations, transport), which is particularly relevant in the context of PD.

Considering this background, the current project aims to contribute to the advance of ACT-based interventions in this field by developing, implementing, and examining the feasibility and preliminary efficacy of the "Empower your mind to embrace your life" intervention. This innovative ACT-based intervention was designed specifically to the context of young-onset PD and will be delivered online, in group format. The feasibility, acceptability and preliminary efficacy will be tested using a parallel-arm study, comparing the intervention with a control condition/waiting list (individuals with an early-onset PD diagnosis that will not receive any type of psychological intervention during the course of the study). Our hypothesis is that by targeting ACT core processes (e.g., acceptance, mindfulness, values), not only functioning and psychological outcomes will improve, but overall quality of life will be positively impacted. For this purpose, a longitudinal design will be implemented, including three assessment moments: baseline, post-intervention and 3-month follow-up (primary outcomes: health-related quality of life and psychopathology indicators -depression and anxiety symptoms; secondary outcomes: ACT core processes [chronic illness-specific and general psychological flexibility, chronic illness-related cognitive fusion, mindfulness], and other relevant outcomes, such as body functionality, shame). All procedures inherent to this research project were approved by the Ethics Committees of the Faculty of Psychology and Educational Sciences, University of Coimbra; Coimbra Local Health Unit (ULS Coimbra), and Hospital da Luz Coimbra. All participants provided their informed consent prior to data collection. The voluntary, confidential and pseudo-anonymized nature of the study was clearly explained. Participants were also informed about the option to decline participation or withdraw at any moment without any negative consequence. All participants will maintain their usual medical treatment, which includes medication for managing PD-related symptoms.

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • Acceptance and Commitment Therapy
  • Parkinson's disease
  • Psychological Flexibility
  • Online group intervention
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Young-onset PD diagnosis confirmed by a neurologist
  • Classification between stages 1 and 2.5 according to the Hoehn \&Yahr scale
  • Aged between 21-65 years
  • Fluent Portuguese speakers

Exclusion criteria

Exclusion Criteria:

  • Currently undergoing any form of psychology intervention
  • Pregnancy
  • Current suicidal ideation
  • Diagnosis of severe psychiatric illness (e.g., severe depression, psychotic illness, bipolar disorder)
  • Cognitive impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Control Group

    Group of participants with young-onset diagnosis of Parkinson's disease (n ≥ 10) not subjected to any psychological intervention within the current study. Participants will be assessed at baseline, at post-intervention (immediately after session 8 of the intervention program), and at 3-month follow-up.

  • Experimental
    Intervention Group

    Group of participants with young-onset diagnosis of Parkinson's disease (n ≥ 10) subjected to an 8-week online psychological intervention delivered in a group format (Empower your mind to embrace your life intervention). Participants in the experimental group will be assessed at baseline, post-intervention (immediately after session 8 of the intervention program), and at 3-month follow-up.

    Behavioral: Empower your mind to embrace your life

Interventions

  • BehavioralEmpower your mind to embrace your life

    An eight-session Acceptance and Commitment Therapy (ACT) for young-onset Parkinson's disease, applied in a group format and delivered online (via videoconferencing).

06

What researchers measure

Primary outcomes

  1. Parkinson's Disease Questionnaire - short form (PDQ-8)

    The PDQ-8 was used to measure Parkinson's disease specific health-related quality of life through 8 items. This self-report instrument covers domains such as mobility, activities of daily living, emotional well-being, social support, communication, cognition, bodily discomfort and stigma. Each item is answered on a five-point Likert scale (ranging from 0 = Never; 4 = Always or cannot do at all). Higher scores on PDQ-8 represent poor health-related quality of life. Previous psychometric studies found very good internal consistency values. This measure was validated to the Portuguese population within the scope of this research project and showed good internal consistency.

    Time frame: Baseline, Week 8, 3-month follow-up

  2. Hospital Anxiety and Depression Scale (HADS)

    The HADS is a self-report measure designed to assess the presence and severity of depressive and anxiety symptoms over the past week. This instrument comprises 14 items rated on a 4-point Likert scale ranging from 0 (Did not apply to me at all) to 3 (Applied to me very much or Most of the time). Higher scores indicate greater depression and anxiety symptomatology. The HADS presented good internal consistency in the original and in the Portuguese versions.

    Time frame: Baseline, Week 8, 3-month follow-up

Secondary outcomes

  1. Psy-Flex for Chronic Illness (Psy-Flex-CI)

    The Psy-Flex-CI assesses chronic illness-related psychological flexibility through 6 items, each referring to one of the six core ACT processes. Participants were instructed to answer according to a 5-point Likert scale (1 = Almost never; 5 = Almost always). This self-report measure was developed and validated within the scope of this research project and presents good psychometric properties.

    Time frame: Baseline, Week 8, 3-month follow-up

  2. Multidimensional Psychological Flexibility Inventory - 24 (MPFI-24)

    The MPFI-24 is a self-report measure that assesses psychological flexibility and inflexibility. The scale consists of 24 items answered on a 6-point Likert scale (ranging from 1 = Never true to 6 = Always true), referring to the last 2 weeks. The scores can be averaged to create a composite score representing global psychological flexibility and inflexibility, respectively. Previous psychometric information demonstrates adequate psychometric properties, including good internal consistency values.

    Time frame: Baseline, Week 8, 3-month follow-up

  3. Cognitive Fusion Questionnaire - Chronic Illness (CFQ-CI)

    The CFQ-CI is a 7-item measure of cognitive fusion specifically related to the experience of having a chronic illness and its symptomatology. Items are rated on a 7-point Likert scale ranging from 1 (Never true) to 7 (Always true). CFQ-CI has demonstrated excellent internal reliability.

    Time frame: Baseline, Week 8, 3-month follow-up

  4. The Mindful Attention and Awareness Scale (MAAS)

    The MAAS is a self-report measure of mindfulness at a trait-level, designed to assess attention and awareness of present moment daily activities. The scale consists of 15 items rated on a 6-point Likert scale (1 = Almost always; 6 = Almost never). Higher scores reflect greater dispositional mindfulness. This instrument has demonstrated good internal consistency.

    Time frame: Baseline, Week 8, 3-month follow-up

  5. External and Internal Shame Scale (EISS)

    The EISS consists of 8 items that assess the experience of external ("Other people see me as not being up to their standards.") and internal ("I am different and inferior to others.") shame. Items are answered according to a 5-point Likert scale (0 = Never to 4 = Always), with higher scores indicating greater shame feelings. The scale presented good internal consistency.

    Time frame: Baseline, Week 8, 3-month follow-up

  6. Functionality Appreciation Scale (FAS)

    This 7-item self-report scale evaluates functionality appreciation (e.g., "I appreciate my body for what it is capable of doing"). Items are answered in a 5- point Likert scale ranging from 0 (Never) to 5 (Always), with higher scores indicating greater body functionality appreciation. The scale presented good internal consistency.

    Time frame: Baseline, Week 8, 3-month follow-up

  7. The Work and Social Adjustment Scale (WSAS)

    The WSAS is a 5-item measure of perceived functional impairment in daily activities that evaluate the extent of disease interference in several life areas (e.g., work, family, interpersonal relations, social and private leisure/hobbies activities, and home management). Items are answered on a 9-point scale (0 = not at all, 8 = severely). Higher scores reflect higher functional impairment. This instrument showed good internal consistency across several different health conditions.

    Time frame: Baseline, Week 8, 3-month follow-up

Other outcomes

  1. Patient Health Questionnaire - 9 (PHQ-9)

    This brief questionnaire is a screening tool based on the DSM-IV criteria for major depressive disorder that assess the severity of depression symptoms (e.g., depressed mood, loss of interest, fatigue, and suicidal ideation). The scale consists of 9 items rated on a 4-point Likert scale (0 = Not at all, 3 = Nearly every day). The scale also comprises an additional item assessing the impact of symptoms on functioning (ranging from Not difficult at all to Extremely difficult). Higher scores indicate more severe depression symptoms. The scale showed good internal consistency.

    Time frame: Baseline

  2. Non-motor Symptoms Questionnaire (NMSQuest)

    This instrument was designed to detect Parkinson's disease specific non-motor manifestations in several domains (e.g., depression and anxiety symptoms, cardiovascular, sexual function, sleep disorder) and comprises 30 items. Each item is answered according to a "yes" or "no" scale. Higher scores indicate higher frequency of non-motor manifestations.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • CINEICC
    Coimbra, 3000-115, Portugal
    Recruiting
    • Inês Matos-Pina, MSc · Contactinescpina@hotmail.com · +351968766690
    • Cláudia Ferreira, PhD · Contact
    • Inês Matos-Pina, MSc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data (IPD) will not be shared in accordance with data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 14 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07310147
Lead sponsor
University of Coimbra
Collaborators
Foundation for Science and Technology, Portugal
Responsible party
Inês Carolina Andrade Matos Pina (Principal Investigator, University of Coimbra) — Principal investigator
First posted
Dec 30, 2025
Start date
Apr 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Inês Matos-Pina, MSc
Contact
inescpina@hotmail.com
+351968766690
Claudia Ferreira, PhD
Contact
claudiaferreira@fpce.uc.pt
Inês Matos-Pina, MSc
principal investigator · CINEICC - Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences of the University of Coimbra
Cláudia Ferreira, PhD
principal investigator · CINEICC - Center for Research in Neuropsychology and Cognitive Behavioral Intervention, Faculty of Psychology and Educational Sciences of the University of Coimbra
Mariana Moura-Ramos, PhD
principal investigator · Unidade Local de Saúde de Coimbra (ULS Coimbra)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion